Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO only. Need evaluate transcript against question. Need determine if management account of reported period (Q4 2022) built substantially around real business activity that crossed from not-happening to happening partway through period or just around edges, and management makes clear newly started activity still completing climb, so period's reported numbers averaged before/after and sit below level business already running. Need parse transcript. We need identify if management describes concrete business that began during/around period, narrated as starts. Examples: Libtayo approved FDA in combination chemo for first-line NSCLC in November? Approval was in Q4? Actually "Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer" in Q4? They say "in the fourth quarter" ? Let's read: "We also made several important advances across our pipeline during the quarter, notably submission BLA for aflibercept 8mg... Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer..." So Libtayo approval happened during Q4? It says received FDA approval. Then Marion: "Customer ordering has accelerated following the chemotherapy combination approval last November. We are working to maximize launch uptake..." So Libtayo in lung cancer combination approval in November (partway through Q4) and customer ordering accelerated following approval. That is a real start? It is a label expansion/approval, launch. But did it generate revenue in Q4? They say U.S. net sales grew 36% to $110 million with contributions across all indications. Customer ordering has accelerated following approval. Early launch indicators positive. This might be a "start" but is it central? Maybe. Other potential: Dupixent approvals in prurigo nodularis in Europe in December; eosinophilic esophagitis in US? They said Dupixent was approved for prurigo nodularis in Europe in December. In 2022, became first treatment for prurigo nodularis and first in US for eosinophilic esophagitis. Also European approval for EoE this week (after period). But Q4 included launches? Marion says U.S. Q4 sales grew with additional contributions from recent launches in EoE and prurigo nodularis.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.